AVAlessio Vigani

Alessio Vigani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alessio Vigani has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Claudia Iannucci

    Department of Clinical Veterinary Medicine, Division of Small Animal Emergency and Critical Care, Vetsuisse Faculty University of Zurich Zurich Switzerland

    5 shared publications
  • Claudia Iannucci

    Department of Clinical Veterinary Medicine, Division of Small Animal Emergency and Critical Care, Vetsuisse Faculty University of Zurich Zurich Switzerland

    3 shared publications
  • Ana Rostaher

    Dermatology Unit, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, 8057 Zurich, Switzerland

    2 shared publications
  • Barbara Steblaj

    Section of Anaesthesiology, Department of Clinical Diagnostics and Services, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland

    2 shared publications
  • Christine A. Culler

    Department of Clinical Sciences, College of Veterinary Medicine North Carolina State University Raleigh North Carolina USA

    2 shared publications
  • Claude Favrot

    Dermatology Unit, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, 8057 Zurich, Switzerland

    2 shared publications

Latest Publications

  • Open Access

    Clinical response of acute idiopathic polyradiculoneuritis treated with therapeutic plasma exchange in four dogs

    by Valentina E R Dazio, Claudia Iannucci, Franziska B Meyer, Lorenzo Golini, Alessio Vigani

    Acute idiopathic polyradiculoneuritis (AIP) is an immune-mediated peripheral neuropathy in dogs for which no specific treatment has been established in veterinary medicine. In human medicine, therapeutic plasma exchange (TPE) is a standard treatment for Guillain–Barré syndrome, a clinically analogous condition. In this case series, we describe 4 dogs diagnosed with AIP and treated with TPE. All dogs received 3 consecutive TPE sessions, processing between 4.2 and 4.8 total dog plasma volumes. Motor function improvement was observed after the first session in all cases, with near-complete neurological recovery at discharge. No adverse effects were reported. During follow-up (2-12 months), 3 dogs remained disease-free, and 1 dog experienced a recurrence that subsequently resolved. These cases suggest that TPE might promote rapid clinical improvement in dogs with AIP, representing a promising emergency treatment option for dogs with severe and rapidly progressive neurological deficits.

  • Open Access

    Evaluation of the Use of a Medium Cut‐Off Dialyser Theranova 400 for Severe Metaldehyde Intoxication in Three Dogs: Dialytic Clearance and Therapeutic Response

    by Maxime Rodary, Claudia Iannucci, Andreas F. Lehner, Birgit Puschner, John P. Buchweitz, Alessio Vigani

    Objective: To describe the clinical utility and toxin removal kinetics of a commercially available medium cut‐off (MCO) haemodialyser as emergent treatment of severe metaldehyde intoxication in three dogs. Series Summary: Three dogs presented to the emergency department with severe acute neurological signs, including seizures and incoercible tremors following metaldehyde ingestion. Medical therapy, including gastric decontamination and intravenous lipid emulsion, was unsuccessful in improving the neurological condition in all three dogs. Haemodialysis (HD) with an MCO dialyser was performed as emergency treatment to control the clinical signs of intoxication. Resolution of neurological signs was achieved in all dogs within a 4‐h HD session without adverse effects. Metaldehyde concentration was measured serially during each treatment. Drug extraction rate, clearance and mass elimination by the MCO dialyser were calculated. The dialytic clearance was 12.5 times higher than the measured intrinsic clearance. Unique Information Provided: This case series describes the clinical efficacy of an MCO dialyser in the treatment of severe metaldehyde intoxication in dogs and provides unique insights on the metaldehyde clearance kinetics through an MCO dialyser.

  • Quantitative Assessment of TPE Antibody Removal and Clinical Response in a Dog With Severe Type III Hypersensitivity Reaction and AKI due to Human Albumin Administration

    by Gwenda Yui Pargätzi, Claudia Iannucci, Marina Luisa Michela Meli, Theres Meili, Tommaso Rosati, Alessio Vigani

    Objective: To describe the successful removal of antihuman albumin antibodies by therapeutic plasma exchange (TPE) in a dog with signs of delayed type III hypersensitivity reaction (tIIIHr), including acute kidney injury (AKI), secondary to administration of human serum albumin (HSA). Case Summary: A 9‐month‐old dog was presented with an infected wound and treated with vacuum‐assisted closure. A 28‐h infusion of 20% HSA was administered to the dog postoperatively to treat persistent hypoalbuminemia during hospitalization. Seventeen days later, the dog returned for acute periorbital swelling. Clinical signs improved after standard treatment for a nonspecific allergic reaction. Five days later, the dog developed persistent vomiting, generalized subcutaneous edema, and ecchymoses on the ventral abdomen. Severe azotemia with proteinuria led to the diagnosis of acute glomerulonephritis. A delayed tIIIHr secondary to HSA administration was suspected. Two sessions of TPE were performed on consecutive days. Complete resolution of clinical signs, including azotemia, occurred after the second TPE session, and the dog was discharged 5 days later in good clinical condition. The urine protein:creatinine ratio normalized within 2 weeks of TPE. Antihuman albumin antibody concentrations were measured by indirect ELISA in the patient's plasma and in the plasma removed by TPE. New or Unique Information: For the first time, antihuman albumin antibodies have been measured before and after treatment with TPE in a dog with clinical signs of delayed tIIIHr, demonstrating the effective removal of antibodies. Based on these findings, TPE could be considered for the treatment of severe tIIIHr after xenotransfusion.

  • Open Access

    Selective Removal of Plasma Proteins by Double-Filtration Plasmapheresis in Canine Blood: An Ex Vivo Study and Retrospective Report of In Vivo Clinical Treatments in Three Dogs

    by Roberta Troia, Claudia Iannucci, Lisa Niemann, Alessio Vigani

    Double-filtration plasmapheresis (DFPP) is a plasma-exchange modality that allows selective clearance of high-molecular-weight proteins, potentially minimizing albumin loss and the need for volume replacement. Reports concerning DFPP use in dogs are scarce. This study evaluates the quantitative net loss of different plasma proteins fractions in an ex vivo model using canine blood processed via DFPP. DFPP treatment with INUSpheresis® processing 1.5, 2, and 3 plasma volumes (PVs) was performed. Plasma proteins fractions were measured in the reservoir blood bag at baseline (pre-treatment) and in the effluent bag at the end of each target PV exchanged to calculate the net loss of selected plasma proteins. At 1.5 PV, net globulin and albumin loss was 41 and 25% respectively. At 3 PV, net globulin and albumin loss was 47 and 40%, respectively. Fibrinogen concentration was unmeasurable low in the reservoir blood bag after processing 1.5 PV. INUSpheresis® allows selective plasma proteins removal, with a sparing effect on albumin at 1.5 PV. Selectivity is, however, progressively reduced with incremental target PV. A description of five DFPP treatments in three dogs is additionally presented. Semi-selective protein removal was also demonstrated in vivo, with a significantly lower percentage reduction in albumin compared to total globulin (p = 0.01) and fibrinogen (p = 0.007).

  • Open Access

    Selective Removal of Plasma Proteins by Double Filtration Plasmapheresis in Canine Blood: An Ex-Vivo Study and Retrospective Report of In-Vivo Clinical Treatments in Three Dogs

    by Roberta Troia, Claudia Iannucci, Lisa Niemann, Alessio Vigani

    Double filtration plasmapheresis (DFPP) is a plasma exchange modality that allows selective clearance of high molecular weight proteins, potentially minimizing albumin loss and the need for volume replacement. Reports concerning DFPP use in dogs are scarce. This study evaluates the quantitative net loss of different plasma proteins fractions in an ex-vivo model using canine blood processed via DFPP. DFPP treatment with INUSpheresis processing 1.5, 2 and 3 plasma volumes (PV) was performed. Plasma proteins fractions were measured in the reservoir blood bag at baseline (pre-treatment) and in the effluent bag at the end of each target PV exchanged to calculate the net loss of selected plasma proteins. At 1.5 PV, net globulin and albumin loss was 41 and 25% respectively. At 3 PV, net globulin and albumin loss was 47 and 40%, respectively. Fibrinogen concentration were unmeasurable low in the reservoir blood bag after processing 1.5 PV. INUSpheresis allows selective plasma proteins removal, with sparing effect on albumin at 1.5 PV. Selectivity is however progressively reduced with incremental target PV. A description of five DFPP treatments in three dogs is additionally presented. Semi-selective protein removal was demonstrated also in-vivo, with a significantly lower percentage reduction of albumin compared to total globulin (P=0.01) and fibrinogen (P=0.007).

  • Open Access

    Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical Efficacy

    by Ana Rostaher, Nina Maria Fischer, Alessio Vigani, Barbara Steblaj, Franco Martini, Salina Brem, Claude Favrot, Mitja Kosnik

    Hymenoptera allergens are the main triggers for anaphylaxis in susceptible dogs and humans. Hymenoptera venom specific immunotherapy (VIT), the only disease-modifying treatment, has the potential to prevent future life-threatening reactions in human patients. Prospective clinical data on VIT efficacy in dogs are currently lacking. Therefore, the aim of this study was to show that VIT is not only safe but also efficacious in preventing anaphylaxis in dogs allergic to Hymenoptera. This uncontrolled prospective clinical trial included 10 client-owned dogs with a history of anaphylaxis following repeated Hymenoptera stings. The sensitization to bee and wasp allergens was demonstrated by intradermal testing (IDT) and allergen-specific IgE serology. For VIT induction (induction phase), dogs received a shortened rush immunotherapy protocol with aqueous allergens, which was then followed by monthly injections of 100 µg of alum-precipitated allergen (maintenance phase). VIT efficacy was determined by observing patients’ clinical reactions to re-stings. No systemic adverse events were seen during the induction and maintenance phases. From the seven re-stung dogs, only one developed a mild angioedema at the site of the sting; the remaining dogs were asymptomatic. These results show that VIT represents a safe and effective treatment option for Hymenoptera-allergic dogs.


  • Open Access

    Hymenoptera Venom Immunotherapy in DOGS: Safety and Clinical Efficacy

    by Ana Rostaher, Nina Maria Fischer, Alessio Vigani, Barbara Steblaj, Franco Martini, Salina Brem, Claude Favrot, Mitja Kosnik

    Hymenoptera allergens are the main triggers for anaphylaxis in susceptible dogs and humans. Hymenoptera venom specific immunotherapy (VIT), the only disease-modifying treatment, has the potential to prevent future life-threatening reactions in human patients. Prospective clinical data on VIT efficacy in dogs are currently lacking. Therefore, the aim of this study was to show that VIT is not only safe but also efficacious in preventing anaphylaxis in dogs allergic to Hymenoptera. This uncontrolled prospective clinical trial included 10 client-owned dogs with a history of anaphylaxis following repeated Hymenoptera stings. The sensitization to bee and wasp allergens was demonstrated by intradermal testing (IDT) and allergen-specific IgE serology. For VIT induction (induction phase), dogs received a shortened rush immunotherapy protocol with aqueous allergens, which was then followed by monthly injections of 100 g of alum-precipitated allergen (maintenance phase). VIT efficacy was determined by observing patients’ clinical reactions to re-stings. No systemic adverse events were seen during the induction and maintenance phase. From the seven re-stung dogs, only one developed a mild angioedema at the site of the sting; the remaining dogs were asymptomatic. These results show that VIT represents a safe and effective treatment option for Hymenoptera-allergic dogs.


  • Open Access

    Hemodialysis as emergency treatment of a severe baclofen intoxication in a 3 kg dog

    by Linda Gabba, Claudia Iannucci, Alessio Vigani

    Objective: To describe the clinical efficacy and drug removal kinetics of hemodialysis (HD) as emergency treatment in a small size dog with severe baclofen intoxication.Case description: A 2‐year‐old dog was presented in stupor to the emergency service a few hours after ingestion of up to 25 mg of baclofen. Medical stabilisation was attempted but was unsuccessful in improving the neurological condition and the patient rapidly progressed to coma. A 4‐h session of HD was performed in emergency with near complete resolution of neurological signs and only mild disorientation by the end of the treatment. No adverse side effects occurred during HD. Baclofen concentration was measured serially during the session. Drug extraction ratio, clearance and mass removal by the dialyser were calculated. Dialytic elimination rate constant (Kd) was seven times higher than the intrinsic elimination rate constant (Kintr) and the half‐life (t½) during HD was nearly nine times shorter than the endogenous one.New or unique information provided: This is the first case report providing pharmacokinetic data associated with HD treatment of severe baclofen intoxication in a dog.


  • Open Access

    Diagnosis of post-attenuation neurological signs syndrome in a cat with refractory status epilepticus and clinical response to therapeutic plasma exchange

    by Lisa Niemann, Katrin Beckmann, Claudia Iannucci, Adriano Wang Leandro, Alessio Vigani

    Case summary: An 8-year-old female spayed British Shorthair cat that underwent surgical portosystemic shunt (PSS) attenuation developed progressive neurological signs 7 days postoperatively. Neurological signs progressed, despite medical management, and seizure activity became rapidly refractory to anticonvulsants. The diagnosis of post-attenuation neurological signs (PANS) was made based on the timing of the occurrence of clinical signs following surgery, absence of hyperammonaemia and suggestive MRI findings of the brain. The cat developed status epilepticus that required treatment with general anaesthesia and mechanical ventilation, from which the cat could not be effectively weaned without the recurrence of seizures. Therapeutic plasma exchange (TPE) was performed as a rescue therapy for PANS and associated refractory status epilepticus. A total of two plasma volumes were processed during one single TPE session. The seizure activity resolved immediately after the TPE session, the cat showed progressive improvement of neurological signs and remained stable thereafter. No significant complications associated with the TPE were observed. The cat was discharged 11 days after admission and was fully recovered. Relevance and novel information: This is an unusual report of PANS diagnosed in a cat based on clinical and MRI findings. The cat developed refractory status epilepticus and had a positive outcome following TPE as rescue therapy. The MRI findings in this report could be useful for the diagnosis of PANS in cats. We speculate that TPE could be taken into consideration as a possible therapeutic intervention in PANS syndrome.


  • Open Access

    Centrifugal therapeutic plasma exchange in dogs with immune‐mediated hemolytic anemia (2016–2018): 7 cases

    by Christine A. Culler, Alessio Vigani, Alexandra Z. Ripoll, Alexandra Gareau, Steven E. Suter

    Objective: To describe the technique of centrifugal therapeutic plasma exchange (cTPE) in dogs diagnosed with immune‐mediated hemolytic anemia (IMHA) and summarize the outcome of the procedure.Design: Retrospective review of cTPE performed at North Carolina State University from 2016 to 2018, through a search of the institutional database for cTPE and IMHA.Setting: University teaching hospital.Animals: Seven dogs with confirmed IMHA were presented to a university teaching hospital ICU for cTPE. Six dogs were not responsive to standard medical management with immunosuppressive agents, while 1 dog presented before immunosuppressive agents were begun.Interventions: All dogs underwent multiple cTPE procedures using 1 of 2 commercially available apheresis systems.Measurements and Main Results: At presentation, the median HCT was 0.15 L/L (15.7%) (range, 0.10–0.19 L/L [10.3%–19%]) and the median total serum bilirubin was 32.5 mmol/L (1.9 mg/dl) (range, 15.4–597 mmol/L [0.9–34.9 mg/dl]). The median number of transfusions before cTPE was 1 (range, 1–4), with a median total of infused RBCs of 12.9 ml/kg (range, 8.8–37 ml/kg). cTPE with an exchange of ≥4 times total plasma volumes was used to decrease the level of circulating autoreactive antibodies. The median total plasma volumes exchanged was 4.5 times (range, 2.5–6.5 times) over 2–4 procedures. Anticoagulation was performed using a combination of systemic heparinization and regional citrate in all dogs. Six of 7 dogs (85.7%) were discharged from the hospital and were alive 90 days after discharge. One dog (14%) did not respond to cTPE (∼6.5 times total plasma volume exchanged) and was euthanized.Conclusions: cTPE is a feasible and relatively safe bridging treatment option for the management of canine IMHA.